Key Takeaways
- • Tortugas Neuroscience closed a $106 million combined Seed and Series A financing round led by Cure Ventures, with co-leads The Column Group and AN Venture Partners supporting the Framingham-based neurology biotech.
- • The capital will fund completion of Phase 2 clinical trials for two lead candidates addressing schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies, leveraging a pipeline of assets licensed from Eisai and Hansoh Pharmaceutical.
- • Tortugas was founded by veterans from Sage Therapeutics and focuses on derisked neurological mechanisms with rapid development pathways, positioning the company to advance treatments for large, well-defined brain disorders.
- • The funding round reflects continued institutional appetite for clinical-stage neuroscience assets, with Cure Ventures' involvement signaling confidence in the company's de novo formation model around proprietary technology platforms.
Summary
Tortugas Neuroscience, a Framingham-based neurology-focused biotech, announced a $106 million Seed and Series A financing round on April 21, 2026. The capital infusion targets completion of Phase 2 clinical trials for the company's two lead candidates and broader research and development initiatives. The round was led by Cure Ventures, a life sciences venture capital firm specializing in de novo company formation around groundbreaking technologies, with co-leads The Column Group and AN Venture Partners participating in the Series A.
The company was launched by veterans from Sage Therapeutics with a clinical-stage pipeline of assets licensed from Eisai and Hansoh Pharmaceutical. Tortugas' therapeutic candidates are being evaluated in schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies—indications characterized by large patient populations and well-defined disease mechanisms. The company's strategic approach emphasizes derisked mechanisms of action and accelerated development timelines, differentiating it within the competitive neuroscience venture landscape.
The financing reflects sustained institutional interest in neurology-focused therapeutics. Cure Ventures' lead position underscores confidence in Tortugas' platform and the founding team's track record from Sage Therapeutics, a mature player in psychiatric and neurological disorders. The participation of The Column Group and AN Venture Partners adds experienced life sciences investors with established track records in clinical-stage asset development and commercialization strategy.
The company was launched by veterans from Sage Therapeutics with a clinical-stage pipeline of assets licensed from Eisai and Hansoh Pharmaceutical. Tortugas' therapeutic candidates are being evaluated in schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies—indications characterized by large patient populations and well-defined disease mechanisms. The company's strategic approach emphasizes derisked mechanisms of action and accelerated development timelines, differentiating it within the competitive neuroscience venture landscape.
The financing reflects sustained institutional interest in neurology-focused therapeutics. Cure Ventures' lead position underscores confidence in Tortugas' platform and the founding team's track record from Sage Therapeutics, a mature player in psychiatric and neurological disorders. The participation of The Column Group and AN Venture Partners adds experienced life sciences investors with established track records in clinical-stage asset development and commercialization strategy.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.